The Atrial Fibrillation Registry (The FLOW-AF Registry): Insights From the United Arab Emirates—Patient Characteristics, Treatment, and One-Year Outcomes

IF 2.6 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Journal of Cardiovascular Electrophysiology Pub Date : 2025-02-10 DOI:10.1111/jce.16598

Moutaz El Kadri, Khalid AlMuti, Amrish Agrawal, Nooshin Bazargani, Mohamed Fathy Soliman Gamaleldin, Haytham Mohamed Ahmed, Omneya Hassanain, Natasha Khalife, Ghazi Radaideh, Mohamed Magdy, Wael A. Almahmeed

{"title":"The Atrial Fibrillation Registry (The FLOW-AF Registry): Insights From the United Arab Emirates—Patient Characteristics, Treatment, and One-Year Outcomes","authors":"Moutaz El Kadri, Khalid AlMuti, Amrish Agrawal, Nooshin Bazargani, Mohamed Fathy Soliman Gamaleldin, Haytham Mohamed Ahmed, Omneya Hassanain, Natasha Khalife, Ghazi Radaideh, Mohamed Magdy, Wael A. Almahmeed","doi":"10.1111/jce.16598","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The epidemiological landscape and treatment efficacy of atrial fibrillation (AF) in the Middle East, notably in the United Arab Emirates (UAE), remain under-explored, presenting a distinct demographic and clinical pattern compared to Western populations. The FLOW-AF Registry aimed to bridge this knowledge gap by examining the characteristics, treatment patterns, clinical outcomes, and healthcare resource utilization (HCRU) of newly diagnosed non-valvular atrial fibrillation (NVAF) patients in the UAE, contributing to the scant literature on NVAF management in the region.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This multicenter, prospective observational study enrolled patients diagnosed with NVAF across six sites in the UAE. Data were collected on demographics, medical history, treatment decisions, clinical outcomes, and HCRU over a 12-month observation period.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 198 patients were enrolled, with a mean age of 63.44 years. Mean CHA₂DS₂-VASc and HAS-BLED scores at baseline were 2.95 and 1.76, respectively. Most patients (55.77%) were prescribed non-vitamin K antagonist oral anticoagulants (NOACs). One-year incidence rates for major clinical events were 6.7% for all-cause mortality, 2.8% for bleeding complications, and 0.6% for myocardial infarction. No strokes were reported during the study period.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The FLOW-AF Registry provides valuable insights into NVAF management in the UAE, demonstrating a distinct patient profile and a preference for NOACs. The NVAF cohort in the UAE was characterized by a younger demographic with lower risk scores and lower rate of clinical events relative to global counterparts. The findings underscore the evolving approach to AF management in the UAE, suggestive of a shift towards NOAC use but also highlights the need for ongoing research to fully understand long-term outcomes and validate current treatment paradigms in the UAE.</p>\n </section>\n </div>","PeriodicalId":15178,"journal":{"name":"Journal of Cardiovascular Electrophysiology","volume":"36 4","pages":"813-823"},"PeriodicalIF":2.6000,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jce.16598","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Electrophysiology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jce.16598","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The epidemiological landscape and treatment efficacy of atrial fibrillation (AF) in the Middle East, notably in the United Arab Emirates (UAE), remain under-explored, presenting a distinct demographic and clinical pattern compared to Western populations. The FLOW-AF Registry aimed to bridge this knowledge gap by examining the characteristics, treatment patterns, clinical outcomes, and healthcare resource utilization (HCRU) of newly diagnosed non-valvular atrial fibrillation (NVAF) patients in the UAE, contributing to the scant literature on NVAF management in the region.

Methods

This multicenter, prospective observational study enrolled patients diagnosed with NVAF across six sites in the UAE. Data were collected on demographics, medical history, treatment decisions, clinical outcomes, and HCRU over a 12-month observation period.

Results

A total of 198 patients were enrolled, with a mean age of 63.44 years. Mean CHA₂DS₂-VASc and HAS-BLED scores at baseline were 2.95 and 1.76, respectively. Most patients (55.77%) were prescribed non-vitamin K antagonist oral anticoagulants (NOACs). One-year incidence rates for major clinical events were 6.7% for all-cause mortality, 2.8% for bleeding complications, and 0.6% for myocardial infarction. No strokes were reported during the study period.

Conclusion

The FLOW-AF Registry provides valuable insights into NVAF management in the UAE, demonstrating a distinct patient profile and a preference for NOACs. The NVAF cohort in the UAE was characterized by a younger demographic with lower risk scores and lower rate of clinical events relative to global counterparts. The findings underscore the evolving approach to AF management in the UAE, suggestive of a shift towards NOAC use but also highlights the need for ongoing research to fully understand long-term outcomes and validate current treatment paradigms in the UAE.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

房颤登记（FLOW-AF登记）：来自阿拉伯联合酋长国的见解-患者特征，治疗和一年的结果。

背景：中东地区，特别是阿拉伯联合酋长国（UAE）的房颤（AF）的流行病学概况和治疗效果仍未得到充分研究，与西方人群相比，房颤呈现出独特的人口统计学和临床模式。FLOW-AF注册旨在通过检查阿联酋新诊断的非瓣膜性心房颤动（NVAF）患者的特征、治疗模式、临床结果和医疗资源利用（HCRU）来弥合这一知识差距，从而弥补该地区关于NVAF管理的文献不足。方法：这项多中心、前瞻性观察性研究纳入了阿联酋六个地区诊断为非瓣膜性房颤的患者。收集了12个月观察期的人口统计学、病史、治疗决策、临床结果和HCRU数据。结果：共入组198例患者，平均年龄63.44岁。基线时平均CHA₂DS₂-VASc和ha - bled评分分别为2.95和1.76。大多数患者（55.77%）使用非维生素K拮抗剂口服抗凝剂（NOACs）。主要临床事件的1年发生率为：全因死亡率6.7%，出血并发症2.8%，心肌梗死0.6%。在研究期间没有中风的报道。结论：FLOW-AF Registry为阿联酋的非瓣膜性房颤管理提供了有价值的见解，显示了独特的患者概况和对NOACs的偏好。与全球同行相比，阿联酋的NVAF队列的特点是人口结构更年轻，风险评分更低，临床事件发生率更低。研究结果强调了阿联酋AF管理方法的演变，表明向NOAC使用的转变，但也强调了正在进行的研究的必要性，以充分了解阿联酋的长期结果并验证当前的治疗模式。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Cardiovascular Electrophysiology 医学-心血管系统

CiteScore

5.20

自引率

14.80%

发文量

433

审稿时长

3-6 weeks

期刊介绍： Journal of Cardiovascular Electrophysiology (JCE) keeps its readership well informed of the latest developments in the study and management of arrhythmic disorders. Edited by Bradley P. Knight, M.D., and a distinguished international editorial board, JCE is the leading journal devoted to the study of the electrophysiology of the heart.